0.06
-6.25%
Close of 9 Nov 2026, in AUD
Search any instrument
Reference data, closing prices and charts across 45,000 companies, plus crypto, commodities and currencies.
About Neurizon Therapeutics
Its shares trade on ASX under the ticker NUZ.AX. It has been listed since 5 October 2001. In the fiscal year to 30 June 2024, it reported revenue of A$866,200 and a net loss of A$7.7m. At that date it held total assets of A$11.1m and shareholders' equity of A$10.2m.
PharmAust Ltd. is a pharmaceutical company, which provides products and services in synthetic and medicinal chemistry to the drug discovery and pharmaceutical industries. The company is headquartered in Nedlands, Western Australia. The company went IPO on 2001-10-05. The principal activities of the Company are to develop its own drug discovery intellectual property, namely approximately three platforms for the treatment of different types of cancers in humans and animals, as well as providing specialized medicinal and synthetic chemistry services on a contract basis to clients. The firm's segments are Corporate and Pharmaceutical. The Pharmaceutical segment provides products and services in synthetic and medicinal chemistry to the drug discovery and pharmaceutical industries. The Corporate segment covers all the corporate overhead expenses. Its subsidiaries include Pitney Pharmaceuticals Pty Ltd, which is engaged in business of developing therapeutic cancer products, and Epichem Pty Ltd, which offers a range of rare and hard to find pharmaceutical impurities, degradants and metabolites of active ingredients and excipients, particularly for over-the-counter and generic drugs.
Figures and description from our data supplier, not checked against the company's own report.
Company facts
- Sector
- Health Care
- Industry
- Pharmaceuticals
- Listed since
- 5 Oct 2001
- Employees
- 52
- Website
- pharmaust.com ↗
Leadership
Pay as last reported
- Mr. Sergio DuchiniNon-Executive Chairman of the Board
- Dr. Michael ThurnChief Executive Officer, Managing Director, Director, since 2023
- Mr. John ClarkChief Operating Officer, since 2024
- Dr. Nicky WallisChief Scientific Officer
- Ms. Fiona MilnerGeneral Manager - Epichem Pty Ltd
- Mr. Stefan RossCompany Secretary
- Mr. Marcus HughesNon-Executive Director
- Dr. Kathryn MacfarlaneNon-Executive Director
Environmental, social and governance
Scores out of 100, from our data supplier
- Overall
- 0
- Environment
- 0
- Social
- 0
- Governance
- 0
SWOT analysis
AI-generated by our data supplier. Not written or checked by our editors.
Strengths
- Company has 52 employees and operates in the Pharmaceuticals sector.
- The company has a history of IPO since 2001-10-05.
- It provides specialized medicinal and synthetic chemistry services to clients.
Weaknesses
- The company's website is listed as http://www.pharmaust.com/ which may not be the correct domain for Neurizon Therapeutics Ltd.
- The source description refers to PharmAust Ltd. instead of Neurizon Therapeutics Ltd.
- The company's principal activities include developing drug discovery intellectual property for cancer treatments, which may be a high-risk area.
Opportunities
- The company can leverage its subsidiaries for expanding its product offerings.
- The Pharmaceutical segment provides services to drug discovery and pharmaceutical industries, which could lead to new contracts.
- The company's focus on cancer treatments may align with growing market demands.
Threats
- The source description is untrusted and contains conflicting information about the company name.
- The company's reliance on cancer treatment platforms may face regulatory challenges.
- The use of an incorrect website domain could lead to confusion and loss of credibility.
Sources and methodology
- Data on this tab
- Our data supplier
- Chart on the Overview
- TradingView
Nothing here is investment advice. Prices can be delayed or wrong, so check with the exchange before relying on them. Data for this page. How we cover markets.